Soiken Holdings Inc. (2385) AI Stock Analysis

• Market Cap: ¥4.16B
• Dividend Yield: 3.14%
• Average Volume (3M): 141.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: -25.31%
• EPS Growth: -61.72%
• Country: JP
• Employees: 90
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): 2.76
• Shares Outstanding: 26,158,200
• 10 Day Avg. Volume: 44,600
• 30 Day Avg. Volume: 141,329
• PEG Ratio: -0.44
• Price to Book (P/B): 0.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

Soiken Holdings Inc. faces substantial financial difficulties with declining revenues and negative profitability, despite a strong balance sheet. The technical indicators point to a bearish trend, and the valuation metrics further highlight the company's struggles. These factors combine to yield a low overall stock score, emphasizing the need for strategic operational improvements.

Soiken Holdings Inc. Business Overview & Revenue Model

Company Description

Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for physician-led pharmaceutical clinical research, health checkups, and specific health guidance; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.

How the Company Makes Money

Soiken Holdings Inc. generates revenue through a multi-faceted business model centered around its healthcare and pharmaceutical services. The company earns income from the development and sale of health supplements and functional foods, which are distributed through various retail and online channels. Additionally, it provides healthcare consulting services, which contribute to its revenue streams. Partnerships with other healthcare companies and institutions play a significant role in expanding its market reach and enhancing its product offerings, thereby increasing its earnings potential.

Soiken Holdings Inc. Financial Statement Overview

Summary

Soiken Holdings Inc. is experiencing significant financial challenges due to declining revenues and profitability issues. While the balance sheet shows strength with zero debt and substantial equity, negative cash flows and profitability metrics indicate operational inefficiencies.

Income Statement

Soiken Holdings Inc. has experienced a significant decline in revenue, with a notable revenue growth decline of -38.01% from the previous year in the TTM period. The company is facing challenges with its profitability, as indicated by negative net profit and EBIT margins, suggesting operational inefficiencies or high costs relative to revenue.

Balance Sheet

The balance sheet shows strong equity and no debt, which indicates a solid financial foundation. The equity ratio is healthy, highlighting the company's reliance on equity financing. However, the return on equity has declined significantly due to negative net income, which is a concern for long-term sustainability.

Cash Flow

The company struggles with cash flow generation, as evidenced by negative free cash flow and operating cash flow in recent periods. The absence of free cash flow growth indicates challenges in converting revenue into cash, which is crucial for operational stability and potential investments.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	5.16B	8.08B	9.35B	8.94B	9.31B
Gross Profit	2.48B	3.72B	4.26B	4.11B	4.25B
EBITDA	-583.21M	750.07M	1.28B	948.13M	1.08B
Net Income	-662.20M	451.85M	809.71M	562.06M	731.69M
Balance Sheet
Total Assets	6.95B	8.24B	8.49B	7.15B	7.41B
Cash, Cash Equivalents and Short-Term Investments	4.79B	5.95B	6.22B	4.26B	4.51B
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	697.02M	1.07B	1.64B	915.00M	1.63B
Stockholders Equity	6.23B	6.97B	6.65B	6.04B	5.61B
Cash Flow
Free Cash Flow	-895.42M	-141.08M	2.09B	-131.65M	820.04M
Operating Cash Flow	-880.82M	-101.55M	2.14B	-107.44M	829.56M
Investing Cash Flow	-14.29M	160.37M	-244.58M	-24.85M	692.97M
Financing Cash Flow	-260.71M	-130.21M	-129.94M	-131.25M	-102.63M

Soiken Holdings Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 159.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2385, the sentiment is Positive. The current price of 159 is below the 20-day moving average (MA) of 162.51, above the 50-day MA of 156.69, and above the 200-day MA of 138.41, indicating a neutral trend. The MACD of 0.54 indicates Positive momentum. The RSI at 50.32 is Neutral, neither overbought nor oversold. The STOCH value of 42.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2385.

Soiken Holdings Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	71 Outperform	¥4.58B	18.59		―	18.71%	33.40%
4594	55 Neutral	¥6.91B	―		―	1473.61%	22.80%
2342	52 Neutral	¥2.88B	―		1.84%	-0.60%	-23595.19%
Sector *	52 Neutral	$7.47B	-0.04	-63.86%	2.34%	16.17%	0.25%
2385	43 Neutral	¥4.16B	―		3.14%	-25.31%	-61.72%
4881	38 Underperform	¥4.30B	―		―	1056.04%	21.63%
4591	37 Underperform	¥4.91B	―		―	-96.64%	8.92%